Galderma

From Wikipedia, the free encyclopedia

Galderma
TypePrivate company
IndustryDermatology
Pharmaceuticals
Founded1981; 40 years ago (1981)
HeadquartersGalderma Pharma SA/Galderma SA Lausanne, Switzerland
Key people
Flemming Ørnskov, CEO
RevenueCHF 2.8 billion in 2018
OwnerConsortium including EQT, Adia, GIC, PSP Investments
Number of employees
4,600
Websitewww.galderma.com

Galderma S.A. is a Swiss pharmaceutical company specializing in dermatological treatments and skin care products. Formerly a subsidiary of L'Oréal and Nestlé, it has been held by a consortium of private institutional investors since 2019.

About[]

Galderma was formed in 1981 as a joint venture between Nestlé and L'Oréal, then it became a subsidiary of Nestlé.[1] Since 2019, it belongs to an investment fund. The company, headed by president and CEO Flemming Ørnskov (ex-Shire), has 33 sites in 100 countries[2] with a worldwide network of distributors and employs more than 4,600 people. The headquarters is based in Lausanne, Switzerland. In 2021, the slogan of Galderma is "Advancing dermatology for every skin story".[3]

History[]

The origins of Galderma date back to 1961 and the founding of the Owen dermatology company in Dallas, Texas, USA by M. Owen.

In 1979, Professor Hans Schaefer founded the International Center for Dermatological Research (CIRD) in Sophia Antipolis, with the support of the CEO of L'Oréal, François Dalle, who wanted to diversify his cosmetic research into the drug sector. At the same time, Nestlé, which also had ambitions in dermatology bought the Owen laboratory.

L'Oréal and Nestlé joined forces to create Galderma in 1981 (CIRD became Galderma R&D). It was a joint venture between the two companies.[4]

In 2007, the Galderma Global Corporate Campaign won the 's International Award of Excellence.

In 2010, sales reached 1.2 billion euros, an increase of 16.1% over 2009.[citation needed]

Galderma expanded by specializing in the research, development and commercialization of products for dermatology (skin care) patients. It reached a significant size, with 38 subsidiaries present in 100 countries in the 2010s.[2] It diversified into aesthetic medicine products with the botulinum toxin Azzalure, a field in which it strengthened in 2010 with the acquisition of the Swedish medical-device company Q-Med.[5]

In 2014, Nestlé bought back all the shares from L'Oréal, thus creating a new unit of Nestlé group called Nestle Skin Health. The transaction had a value of €3.1 billion (US$4.23 billion) and was paid for by Nestlé with 21.2 million L'Oréal shares.[6] L'Oréal paid €3.4 billion (US$4.63 billion) for the remaining 27.3 million shares.[6]

In 2019, Nestlé sold Galderma for $10.2 billion[7][8] to a consortium comprising the EQT VIII fund, Luxinva (a wholly owned subsidiary of Abu Dhabi Investment Authority), PSP Investments and other institutional investors. Since then, it has been the largest independent dermatology company in the world.[9]

Activities[]

Galderma is specialized in the research, development and commercialization of skin care products and treatments across aesthetics, consumer care and prescription medicine.

Galderma provides a range of over-the-counter and prescription dermatological products for skin care, aesthetics and treatment of conditions including acne, rosacea, psoriasis and other steroid-responsive dermatoses (SRD), onychomycosis (fungal nail infections), pigmentary disorders, skin cancer and skin aging. Galderma's activities are divided into three business units: aesthetics, consumer care and prescription medicine. Galderma's products are sold in more than 100 countries.

Aesthetics[]

Galderma develops aesthetic solutions for patients and the company is considered one of the world leaders in the aesthetic and corrective dermatology market.[10]

In 2007, Galderma and Ipsen signed a licensing agreement for the distribution of the botulinum toxin Dysport, known as Azzalure in the European Union, for the improvement of glabellar lines (frown lines between the eyes). More than 40 million treatments have been performed in the United States and the European Union.[11]

The main brands are Restylane, Azzalure, Dysport and Sculptra.

Consumer care[]

Galderma's products are available over-the-counter to consumers.

The main consumer care brands are Cetaphil, with its range of skin care products for all ages; Proactiv for the prevention and treatment of acne; Benzac and Differin OTC for mild-to-moderate acne; and Loceryl, used to treat fungal nail infections.

Prescription Medicine[]

This activity aims to provide solutions for patients with skin conditions that have physical, psychological or social consequences. Disease areas are atopic dermatitis, dermato-oncology and psoriasis.

The main brands are Aklief, Benzac, Cetaphil, Epiduo, Epiduo Forte, Loceryl, Differin, Soolantra, Mirvaso,Oracea and Metvix.

Research and development[]

The company invests substantially in research and development and sources new treatments from its own activities and from its partnerships with others. It divides its research and development departments between four sites:

  • Lausanne, Switzerland
  • Uppsala, Sweden
  • Fort Worth, Texas
  • Bridgewater, New Jersey

Production[]

Galderma has manufacturing facilities at the following locations:

  • The Alby-sur-Chéran plant in France, inaugurated in 1994, supplies over 70 countries.
  • The Baie d'Urfé (Montreal) facility in Canada started production in 2000 and supplies North America.
  • The plant in Uppsala, Sweden, manufactures aesthetic and corrective products.
  • The Hortolândia site in the state of São Paulo, Brazil serves South America.

Governance[]

  • Flemming Ørnskov, chief executive officer
  • Thomas Dittrich chief financial officer
  • Cécile Dussart, vice president, head of global operations

Notes and references[]

  1. ^ Nestlé
  2. ^ Jump up to: a b "Manufacturing". Galderma. Retrieved 1 April 2021.
  3. ^ "Home". Galderma. Retrieved 6 April 2021.
  4. ^ "Nestlé exchanges stake in L'Oreal for Galderma". AP NEWS. Retrieved 1 April 2021.
  5. ^ "UPDATE 2-Galderma bids $967 mln for Swedish implant firm Q-Med". Reuters. 13 December 2010. Retrieved 1 April 2021.
  6. ^ Jump up to: a b Socha, Miles (11 February 2014). "L'Oréal to Buy 8% of Share Capital From Nestlé". WWD. Retrieved 11 February 2014.
  7. ^ "Ex-Shire CEO Flemming Ornskov emerges as Galderma CEO after $10B Nestlé spinout". FiercePharma. Retrieved 1 April 2021.
  8. ^ Schuetze, Silke Koltrowitz, Arno (16 May 2019). "Nestle makeover advances with $10 billion sale of skin health unit". Reuters. Retrieved 1 April 2021.
  9. ^ "Galderma to become the world's largest independent global dermatology company after completion of CHF 10.2 billion carve-out of Nestlé Skin Health". Galderma. Retrieved 1 April 2021.
  10. ^ "Medical Aesthetics Market Top Companies – Johnson & Johnson, Allergan, Galderma, Statistical Data Strategic Planning, Future Investments and Developments By Growing Aesthetic Devices and Services |". Medgadget. 6 December 2019. Retrieved 1 April 2021.
  11. ^ "Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)". www.businesswire.com. 17 November 2020. Retrieved 1 April 2021.

See also[]

Retrieved from ""